Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2020-05-15 Interim / Quarterly Rep…
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Pharmena_Skonsolidowany i jednostkowy raport za I kwartał 2020_podpisany
Interim / Quarterly Report Classification · 100% confidence The document is a table of contents for a quarterly financial report ('raport kwartalny') for the period ending March 31, 2020. It includes detailed sections for consolidated financial statements (income statement, cash flow, financial position, changes in equity) and additional explanatory notes. This structure is characteristic of an Interim/Quarterly Report (IR). Q1 2020
2020-05-15 Polish
Zakończenie prezentacji przemysłowi farmaceutycznemu wyników badań leku 1-MNA we wskazaniu NASH w zakresie informacji niepoufnych - Content (PL)
Management Reports Classification · 95% confidence The document is a formal communication from the Management Board (Zarząd) of PHARMENA S.A., referencing a prior current report (raport bieżący) and detailing the progress of commercialization efforts for a drug candidate (1-MNA) targeting NASH. It discusses ongoing presentations to 'BIG PHARMA' companies, the role of the advisory firm Plexus Ventures, preclinical study results, and the potential financial impact of a successful commercialization. This type of update, focusing on strategic business development, drug pipeline progress, and potential future revenue drivers, is characteristic of an ongoing business update rather than a standardized regulatory filing like a 10-K, an earnings release (ER), or a formal audit report (AR). Since it is a detailed update on business strategy and development, it fits best under Management Reports (MDA), which covers management's explanation of business trends and outlook, or potentially Regulatory Filings (RNS) if it were a general announcement. Given the detailed narrative about the commercialization process and scientific findings, MDA is the most appropriate fit, as it is a management-driven report on operational progress and outlook, even if it is structured as a current report update.
2020-05-13 Polish
Rozszerzenie współpracy z Amazon EU w zakresie sprzedaży produktów - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a short announcement (1548 characters) written in Polish. It refers to a previous report and details an expansion of cooperation with Amazon EU regarding the sale of new cosmetic and veterinary products. The text concludes by stating that this expansion may significantly impact the company's revenues in the coming years. This type of announcement, detailing a significant business development or contract update that impacts revenue/operations, fits best under a general regulatory announcement or a specific business update. Since there is no specific category for 'Business Expansion' or 'Contract Update' that isn't financial (like CAP or TAR), and it is not a formal financial report (10-K, IR, ER), it falls under the general regulatory/miscellaneous filing category, RNS, as per the fallback rule, although it is a specific business update.
2020-04-24 Polish
Udzielenie dostępu do informacji poufnych dot. suplementów diety Menavitin w procesie ich komercjalizacji - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a communication from the Management Board (Zarząd) of PHARMENA S.A. referencing a prior report (raport bieżący) regarding the commercialization process of their Menavitin dietary supplements. It details the progress of granting access to confidential data to pharmaceutical firms via a consulting firm (Plexus Ventures) to secure licensing deals in Europe. This type of update, which discusses ongoing business development, strategic partnerships, and potential future financial impact, aligns best with a general business/strategy update or a report on significant corporate activities that aren't strictly financial results (ER/IR) or management changes (MANG). Since it is an update on the progress of a major project (commercialization/licensing), it fits the description of a general corporate report or announcement. Given the options, and since it is not a formal financial statement, earnings release, or management discussion/analysis, it is most likely a Regulatory Filing (RNS) as a general update on material business progress, or potentially a specific type of Investor Presentation (IP) if it were structured as one, but the format suggests a formal regulatory disclosure. Since it is a detailed update on strategic business progress that could materially affect valuation, and it references a prior 'raport bieżący' (current report), RNS is the most appropriate general regulatory disclosure category for non-standard, material updates.
2020-04-21 Polish
PHR_Wykaz akcjonariuszy posiad. pow. 5% głosów na NWZ w dniu 07 04 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text is titled 'Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Nadzwyczajnym Walnym Zgromadzeniu Pharmena S.A. w dniu 07.04.2020 r.', which translates to 'List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of Pharmena S.A. on 07.04.2020'. This document explicitly details the voting results and the percentage of votes held by major shareholders during a general meeting (in this case, an Extraordinary General Meeting, NWZ). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not an AGM presentation (AGM-R), nor is it a general management announcement (MANG) or a proxy solicitation document (PSI).
2020-04-10 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na NWZ w dniu 07.04.2020 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text, written in Polish, states that the Management Board of PHARMENA S.A. is attaching a list of shareholders holding at least 5% of the votes at the Extraordinary General Meeting (Nadzwyczajnym Walnym Zgromadzeniu) held on 07.04.2020. This content specifically details the results of voting rights or the composition of major shareholders present at a general meeting, which aligns directly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is short and appears to be an announcement accompanying the detailed results.
2020-04-10 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.